A Trial of Felzartamab in Kidney Transplant Recipients With Late Antibody-Mediated Rejection (AMR)

PHASE3RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

December 3, 2024

Primary Completion Date

December 1, 2026

Study Completion Date

June 1, 2027

Conditions
Antibody-mediated Rejection
Interventions
DRUG

Felzartamab

Participants will receive felzartamab by intravenous infusion.

DRUG

Placebo

Participants will receive 0.9% saline solution by intravenous infusion.

Trial Locations (48)

1023

RECRUITING

Auckland City Hospital, Grafton

1090

RECRUITING

Medical University of Vienna, Spitalgasse

2145

RECRUITING

Westmead Hospital, Sydney

4031

RECRUITING

University Hospital Basel, Petersgraben

6150

RECRUITING

Fiona Stanley Hospital, Murdoch

8003

RECRUITING

Hospital del Mar, Ciutat Vella

8035

RECRUITING

Hospital Universitario Vall d'Hebron, Horta-Guinardó

8036

RECRUITING

Hospital Clinic de Barcelona, Calle Villarroel

8091

RECRUITING

Universitätsspital Zürich, Zurich

10117

RECRUITING

Charite University, Berlin

19104

RECRUITING

Penn Medicine - Hospital of the University of Pennsylvania, Philadelphia

20246

RECRUITING

Universitatsklinikum Hamburg-Eppendorf, Hamburg

23298

RECRUITING

Virginia Commonwealth University, Richmond

27705

RECRUITING

Duke University, Durham

31400

RECRUITING

Centre Hospitalier Universitaire (CHU) de Toulouse - Hôpital de Rangueil, Toulouse

32000

RECRUITING

CHU Lyon Hôpital Edouard Herriot, Bordeaux

37232

RECRUITING

Vanderbilt University, Nashville

38700

RECRUITING

CHU Grenoble Alpes Hôpital Michallon, La Tronche

43210

RECRUITING

The Ohio State University, Columbus

44195

RECRUITING

Cleveland Clinic, Cleveland

45219

RECRUITING

University of Cincinnati, Cincinnati

53226

RECRUITING

Medical College of Wisconsin, Milwaukee

55905

RECRUITING

Mayo Clinic, Rochester

60637

RECRUITING

University of Chicago, Chicago

63130

RECRUITING

Washington University, St Louis

66160

RECRUITING

University of Kansas, Kansas City

69003

RECRUITING

Hospices Civils de Lyon - Hôpital Édouard Herriot, Lyon

70112

RECRUITING

Tulane University Health Sciences Center, New Orleans

75390

RECRUITING

UT Southwestern Medical Center, Dallas

77030

RECRUITING

Houston Methodist, Houston

80045

RECRUITING

University of Colorado, Aurora

90033

RECRUITING

University of Southern California, Los Angeles

90048

RECRUITING

Cedars-Sinai Medical Center, Los Angeles

90095

RECRUITING

UCLA, Los Angeles

92408

RECRUITING

Loma Linda, San Bernardino

92868

RECRUITING

Providence Healthcare, Orange

94109

RECRUITING

California Pacific Medical Center, San Francisco

94143

RECRUITING

University of California, San Francisco, San Francisco

98195

RECRUITING

University of Washington Medical Center, Seattle

68198-5331

RECRUITING

University of Nebraska, Omaha

07039

RECRUITING

Cooperman Barnabas Medical Center, West Orange

QLD 4102

RECRUITING

Princess Alexandra Hospital, Woolloongabba

05403-010

RECRUITING

Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Cerqueira César

04038-002

RECRUITING

Fundação Oswaldo Ramos - Hospital do Rim (HRIM), Vila Clementino

T6G 2C8

RECRUITING

University of Alberta, Edmonton

V5Z 1M9

RECRUITING

Vancouver General Hospital, Vancouver

V6T 1Z3

RECRUITING

The University of British Columbia (UBC)/St. Paul's Hospital part of Providence Health Care, Vancouver

H4A 3J1

NOT_YET_RECRUITING

McGill, Montreal

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY

NCT06685757 - A Trial of Felzartamab in Kidney Transplant Recipients With Late Antibody-Mediated Rejection (AMR) | Biotech Hunter | Biotech Hunter